MilliporeSigma Acquires Mirus Bio to Enhance Viral Vector Production
MilliporeSigma acquires Mirus Bio for $600M, enhancing viral vector production capabilities.
Breaking News
Aug 02, 2024
Mrudula Kulkarni

The purchase of Mirus Bio by MilliporeSigma's Life Science
division has closed for an estimated $600 million, subject to regulatory
clearances and the satisfaction of other normal closing conditions.The purchase
is a calculated move towards the company's goal of providing solutions for each
stage of the production of viral vectors. Additionally, it reaffirms the
business's dedication to helping clients advance gene and cell treatments from
preclinical to commercial manufacturing.
"Impressive prospects exist for delivering novel
therapeutic interventions to patients through innovative modalities such as
gene and cell therapies," stated Sebastian Arana, Head of Process
Solutions at Merck KGaA's Life Science division in Darmstadt, Germany.
"Mirus Bio's cutting-edge technology, together with our depth of
experience in bioprocessing and diverse portfolio, will allow us to provide
comprehensive solutions throughout the viral vector value chain and assist with
meet the growing demand for these life-saving therapies.”
Transfection reagent development and marketing, including
TransIT-VirusGEN, is the area of expertise for Mirus Bio. These materials are
essential to the creation of gene treatments based on viral vectors. With the
purchase of the industry-leading transfection reagents from Mirus Bio,
MilliporeSigma can now provide an integrated viral vector production solution
in addition to strengthening its upstream range.